Loading...
•
Jun 30, 2023
Gossamer Bio Q2 2023 Earnings Report
Announced second quarter 2023 financial results and provided business update
Key Takeaways
Gossamer Bio reported a net loss of $42.5 million for the second quarter ended June 30, 2023. The company's cash, cash equivalents, and marketable securities totaled $162.1 million as of June 30, 2023, which, combined with proceeds from a July private placement, is expected to fund operations into the first half of 2026.
Seralutinib Phase 3 PROSERA Study in PAH Patients Expected to Initiate in 3Q23
Additional Data from TORREY Open-Label Extension Expected in 4Q23 or 1Q24
Cash, Cash Equivalents & Marketable Securities totaled $374 Million, as of June 30, 2023, Pro Forma for Gross Proceeds of $212 Million from a Private Placement Financing in July 2023
Net loss for the quarter ended June 30, 2023, was $42.5 million, or $0.45 per share
Gossamer Bio
Gossamer Bio
Forward Guidance
Gossamer Bio anticipates initiating the Phase 3 PROSERA Study in the third quarter of 2023 and expects current funds to support operations into the first half of 2026.